Industry News
Vyluma Announces NMPA Acceptance of NVK002 for Pediatric Myopia in China

Vyluma has announced that the National Medical Products Administration (NMPA) of China has accepted ...

read more
Vyluma Announces NMPA Acceptance of NVK002 for Pediatric Myopia in China
January 31, 2025
AI Optics’ Sentinel Camera Receives FDA 510(k) Clearance for Portable Retinal Imaging

AI Optics, a medical device company specializing in artificial intelligence-driven ophthalmic soluti...

read more
AI Optics’ Sentinel Camera Receives FDA 510(k) Clearance for Portable Retinal Imaging
January 31, 2025
EMA Endorses Macustar's Research on Early AMD Clinical Trials

The European Medicines Agency (EMA) has issued its third Letter of Support to the Macustar consortiu...

read more
EMA Endorses Macustar's Research on Early AMD Clinical Trials
January 30, 2025
Harrow Launches "Harrow Cares" Program in Partnership with Cencora

Harrow, a leading eye care pharmaceutical company in North America, has announced the launch of Harr...

read more
Harrow Launches
January 30, 2025
SeaBeLife Reports Promising In Vivo Results for SBL03 Ophthalmic Gel in Geographic Atrophy

SeaBeLife has announced promising in vivo preclinical results for its investigational drug SBL03, an...

read more
SeaBeLife Reports Promising In Vivo Results for SBL03 Ophthalmic Gel in Geographic Atrophy
January 30, 2025
Viralgen and Axovia Therapeutics Partner to Develop Gene Therapy for Bardet-Biedl Syndrome

Viralgen and Axovia Therapeutics have announced a strategic collaboration to develop and manufacture...

read more
Viralgen and Axovia Therapeutics Partner to Develop Gene Therapy for Bardet-Biedl Syndrome
January 29, 2025
Apellis Pharmaceuticals Secures Australian Approval for Syfovre (Pegcetacoplan) in Geographic Atrophy Treatment

Apellis Pharmaceuticals has announced that the Therapeutic Goods Administration (TGA) of Australia h...

read more
Apellis Pharmaceuticals Secures Australian Approval for Syfovre (Pegcetacoplan) in Geographic Atrophy Treatment
January 29, 2025
Norlase Secures FDA 510(k) Clearance and CE Mark for LYNX Pattern Scanning Laser Indirect Ophthalmoscope

Norlase, a global leader in ophthalmic laser technology, has announced the commercial launch of LYNX...

read more
Norlase Secures FDA 510(k) Clearance and CE Mark for LYNX Pattern Scanning Laser Indirect Ophthalmoscope
January 28, 2025
MERIT Acquires OSOD to Strengthen Early-Stage Ophthalmic Drug Development

MERIT, a global provider of clinical trial endpoint and technology services, has announced the acqui...

read more
MERIT Acquires OSOD to Strengthen Early-Stage Ophthalmic Drug Development
January 27, 2025
Outlook Therapeutics Presents Results from NORSE EIGHT Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics shared results from the NORSE EIGHT clinical trial at the Hawaiian Eye and Reti...

read more
Outlook Therapeutics Presents Results from NORSE EIGHT Trial Evaluating ONS-5010 for the Treatment of Wet AMD
January 27, 2025
More